Immunotherapies: Exploiting the Immune System for Cancer Treatment

Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy

(2017) Deasmond O. Acheampong et al.   PROTEIN AND PEPTIDE LETTERS

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

(2017) Diwakar Davar et al.   Journal for ImmunoTherapy of Cancer

Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma

(2016) Chia-Yen Lu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Abstract 3576: Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load

(2016) Zachary R. Chalmers et al.   CANCER RESEARCH

Lymphocyte-activation gene-3, an important immune checkpoint in cancer

(2016) Yayi He et al.   CANCER SCIENCE

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer

(2016) Lee S. Rosen et al.   CLINICAL CANCER RESEARCH

Microsatellite Instability as a Biomarker for PD-1 Blockade

(2016) J. C. Dudley et al.   CLINICAL CANCER RESEARCH

A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors

(2016) Alexandra Gonzalez et al.   INTERNATIONAL JOURNAL OF CANCER

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies

(2016) Kiyotaka Yoh et al.   INVESTIGATIONAL NEW DRUGS

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

(2016) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of HGF/c-MET signaling pathway in lymphoma

(2016) Bao Quoc Lam et al.   Journal of Hematology & Oncology

A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells

(2016) M. Schmittnaegel et al.   MOLECULAR CANCER THERAPEUTICS

Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma

(2016) Ximena Bonilla et al.   NATURE GENETICS

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immuno-Oncology: The Third Paradigm in Early Drug Development

(2016) Juan Martin-Liberal et al.   Targeted Oncology

Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy

(2016) R. Mandal et al.   Cancer Discovery

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

(2016) D. B. Johnson et al.   Cancer Immunology Research

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

(2016) Gerald S. Falchook et al.   Journal for ImmunoTherapy of Cancer

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

(2015) Soranobu Ninomiya et al.   BLOOD

CD19 chimeric antigen receptor T cell therapy for haematological malignancies

(2015) Sara Ghorashian et al.   BRITISH JOURNAL OF HAEMATOLOGY

Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial

(2015) A. Legat et al.   CLINICAL CANCER RESEARCH

Blinatumomab for the treatment of acute lymphoblastic leukemia

(2015) Jason B. Kaplan et al.   INVESTIGATIONAL NEW DRUGS

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

(2015) Cyrille J. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Therapeutic antibodies: Discovery, design and deployment

(2015) Paul A. Ramsland et al.   MOLECULAR IMMUNOLOGY

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy

(2015) Yanping Xiao et al.   Cancer Discovery

A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma

(2015) Shan-Shan Jiang et al.   Oncotarget

Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules

(2015) M. Schmittnaegel et al.   Cancer Immunology Research

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

(2015) Isabelle Le Mercier et al.   Frontiers in Immunology

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond

(2015) Paolo A. Ascierto et al.   EBioMedicine

Curtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment

(2015) Navjotsingh Pabla et al.   Oncotarget

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

(2014) L. Liu et al.   CLINICAL CANCER RESEARCH

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma

(2014) C. R. Pickering et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Long-Term Functionality of TCR-Transduced T Cells In Vivo

(2014) M. Coccoris et al.   JOURNAL OF IMMUNOLOGY

Entering the mainstream of cancer treatment

(2014) Steven A. Rosenberg   Nature Reviews Clinical Oncology

Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment

(2014) Ulrich H. Weidle et al.   SEMINARS IN ONCOLOGY

KRAS: feeding pancreatic cancer proliferation

(2014) Kirsten L. Bryant et al.   TRENDS IN BIOCHEMICAL SCIENCES

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

(2013) M. J. Besser et al.   CLINICAL CANCER RESEARCH

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

(2013) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy with TCR-Redirected T Cells: Comparison of TCR-Transduced and TCR-Engineered Hematopoietic Stem Cell-Derived T Cells

(2013) L. Starck et al.   JOURNAL OF IMMUNOLOGY

Single-Domain Antibody-Based and Linker-Free Bispecific Antibodies Targeting Fc RIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells

(2013) C. Rozan et al.   MOLECULAR CANCER THERAPEUTICS

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations

(2013) Nicolai Juul Birkbak et al.   PLoS One

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

(2012) P. A. Prieto et al.   CLINICAL CANCER RESEARCH

Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

(2012) L. G. Radvanyi et al.   CLINICAL CANCER RESEARCH

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

(2012) Andrea Wang-Gillam et al.   INVESTIGATIONAL NEW DRUGS

Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment

(2012) Jianjian Jin et al.   JOURNAL OF IMMUNOTHERAPY

Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma

(2012) Shari Pilon-Thomas et al.   JOURNAL OF IMMUNOTHERAPY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth

(2012) Paolo Luraghi et al.   Frontiers in Pharmacology

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer

(2011) Cecily P. Vaughn et al.   GENES CHROMOSOMES & CANCER

Buffered memory: a hypothesis for the maintenance of functional, virus-specific CD8+ T cells during cytomegalovirus infection

(2011) Christopher M. Snyder   IMMUNOLOGIC RESEARCH

The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis

(2011) Catherine E. Steding et al.   IMMUNOLOGY

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

(2010) Leo Luznik et al.   IMMUNOLOGIC RESEARCH

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

(2010) Laurent Derré et al.   JOURNAL OF CLINICAL INVESTIGATION

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

(2010) Chrystelle Brignone et al.   Journal of Translational Medicine

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

(2008) F. O. Smith et al.   CLINICAL CANCER RESEARCH

Monoclonal Antibodies as Innovative Therapeutics

(2008) Janice Reichert   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Molecular cancer therapy: Can our expectation be MET?

(2008) Cristina Migliore et al.   EUROPEAN JOURNAL OF CANCER

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY

Cancer Immunology

(2008) Olivera J. Finn   NEW ENGLAND JOURNAL OF MEDICINE